Prospective Evaluation of the 2022 Optic Neuritis Criteria When Optic Neuritis Is Suspected (GX-ICON)
A Multicenter Prospective Diagnostic Accuracy Study of the 2022 International Criteria for Optic Neuritis and an Antibody-Stratified Adjunct in Acute or Subacute Visual Loss When Optic Neuritis Is Suspected in China
Optic neuritis is an important cause of acute or subacute visual loss. In clinical practice, optic neuritis must often be distinguished from other optic neuropathies, retinal diseases, anterior-segment or ocular media disorders, non-organic visual loss, and other mimics. The 2022 International Criteria for Optic Neuritis were developed to standardize the diagnosis of optic neuritis, but their performance in Chinese clinical settings, where aquaporin-4 immunoglobulin G positive and myelin oligodendrocyte glycoprotein immunoglobulin G positive optic neuritis are relatively common, remains uncertain.
This multicenter prospective observational study is enrolling patients with acute or subacute visual loss or visual dysfunction in whom optic neuritis is included in the differential diagnosis. The study is designed to evaluate the diagnostic performance of the 2022 International Criteria for Optic Neuritis alone and with an antibody-stratified adjunct. The index classifications will be compared with an expert-adjudicated reference-standard diagnosis. No experimental treatment is assigned by the study. All diagnostic tests and treatments are determined by the treating clinicians according to routine clinical care. Study data are collected using a structured protocol-defined case report form.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Gedetailleerde beschrijving
This multicenter prospective observational study evaluates the 2022 International Criteria for Optic Neuritis, alone and with an antibody-stratified adjunct, in patients initially suspected of having optic neuritis. Structured prospective data collection began on January 6, 2025. Each participant contributes one clinical episode. The cohort is not restricted to participants ultimately diagnosed with optic neuritis. Diagnostic testing and treatment are determined by the treating clinicians as part of routine care.
Baseline symptoms and ophthalmic findings are recorded using a structured electronic case report form. Available visual field, optical coherence tomography, magnetic resonance imaging, and laboratory findings are collected. Baseline and follow-up optical coherence tomography are encouraged when clinically feasible but are not required by study participation. Available follow-up findings can support reference-standard adjudication. Absence of follow-up optical coherence tomography alone does not exclude a participant from the primary analysis.
Both index strategies use baseline clinical data and eligible paraclinical information obtained within 3 months after symptom onset for the current episode, based on examination or sample collection dates. Later information will not revise either index classification. The 2022 criteria assign definite optic neuritis, possible optic neuritis, or not optic neuritis using prospectively recorded clinical findings, including actual color vision assessments rather than assumed abnormalities.
The antibody-stratified adjunct described in Table 2 of Liang and colleagues (2026) is applied only to participants with aquaporin-4 immunoglobulin G positivity or clear-positive myelin oligodendrocyte glycoprotein immunoglobulin G results in the index window. Under that framework, acute or subacute visual loss with at least one objective finding consistent with optic neuropathy supports definite optic neuritis; without such an objective finding, the adjunct category is possible optic neuritis. The final index classification is the higher-certainty category assigned by the 2022 criteria or the adjunct, using the hierarchy definite optic neuritis, possible optic neuritis, then not optic neuritis. Participants without either qualifying positive antibody result retain their original 2022 criteria classification. Unavailable antibody results are not treated as negative.
Participants are followed for up to 6 months after enrollment whenever feasible. Reference-standard adjudication uses baseline information and available clinical course, repeat examinations, investigations, treatment response, and alternative diagnoses within this period. The target is whether the current episode represents optic neuritis, not merely whether an antibody-associated disease is present.
For each participant, two experts independently assess the case in two stages. In Stage 1, current and historical aquaporin-4 immunoglobulin G and myelin oligodendrocyte glycoprotein immunoglobulin G results, including directly revealing diagnostic labels, are withheld. Stage 1 judgments are recorded and locked before antibody disclosure. In Stage 2, the same experts reassess the case after receiving available antibody results and relevant assay information. Both stages use otherwise identical case information and the same information cutoff, no later than 6 months after enrollment. At each stage, cases are classified as optic neuritis, non-optic neuritis, or indeterminate. A third expert resolves disagreements under the corresponding information restrictions; Stage 1 disagreements are resolved before disclosure.
At both stages, experts are masked to the index classifications. Personnel assigning or verifying index classifications are masked to the expert reference diagnoses. Masking antibody results from experts does not remove those results from either index strategy. Index classifications and reference diagnoses are recorded separately and finalized before comparative analysis. Stage 2 full-information adjudication is the primary reference standard. Stage 1 provides a supplementary reference for sensitivity analyses and assessment of diagnostic changes after antibody disclosure. Initial agreement between experts is summarized at each stage using percentage agreement and Cohen's kappa.
The primary analysis treats definite optic neuritis as index-positive and not optic neuritis as index-negative; possible optic neuritis is excluded from this conditional binary analysis and reported separately. A secondary low-threshold analysis treats definite or possible optic neuritis as positive. Indeterminate reference diagnoses are excluded from the corresponding binary accuracy calculations but retained in reported category distributions. Definite-classification yield is also compared within the same reference-positive participants, retaining possible classifications as not definite. Newly upgraded cases are described according to their reference diagnoses. First-stage indeterminacy does not exclude a participant from second-stage analyses. Detailed outcome definitions are provided in the outcome measures section.
At initial public registration, recruitment was ongoing, and database lock, formal reference-standard adjudication, final index classification, and the primary diagnostic accuracy analysis had not occurred. The antibody-masked stage is an amendment-added assessment; full-information expert adjudication remains the primary reference standard.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Yi Du, MD, PhD
- Telefoonnummer: +86 771 5356507
- E-mail: duyinapoleon@gmail.com
Studie Locaties
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Werving
- The First Affiliated Hospital of Guangxi Medical University
-
Contact:
- Yi Du, MD, PhD
- Telefoonnummer: +86 771 5356507
- E-mail: duyinapoleon@gmail.com
-
Nanning, Guangxi, China, 530005
- Werving
- The Second Affiliated Hospital of Guangxi Medical University
-
Contact:
- Wenqiao Huang
- Telefoonnummer: +86 771 3277068
- E-mail: wqhuang8674@163.com
-
Nanning, Guangxi, China, 530001
- Werving
- Guangxi Minzu Hospital
-
Contact:
- Meifeng Luo
- Telefoonnummer: +86 771 3131152
- E-mail: luomf9853@qq.com
-
Nanning, Guangxi, China, 530022
- Werving
- Guangxi Jingliang Eye Hospital
-
Contact:
- Mukun Zhao
- Telefoonnummer: +86 771 7980630
-
Nanning, Guangxi, China, 530199
- Werving
- Wuming Hospital of Guangxi Medical University
-
Contact:
- Xiaoyuan Ma
- Telefoonnummer: +86 771 6226473
-
Contact:
- Yihua Huang
-
Qinzhou, Guangxi, China, 535000
- Werving
- The Second People's Hospital of Qinzhou
-
Contact:
- Fangfang Zhang
- Telefoonnummer: +86 777 3682222
-
Wuzhou, Guangxi, China, 543099
- Werving
- Wuzhou Gongren Hospital
-
Contact:
- Jun Yang
- Telefoonnummer: +86 774 2036883
-
Yulin, Guangxi, China, 537099
- Werving
- The First People's Hospital of Yulin
-
Contact:
- Na Li
- Telefoonnummer: +86 775 2683288
-
Contact:
- Qingjuan Zhao
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215000
- Werving
- Lixiang Eye Hospital of Soochow University
-
Contact:
- Yinbin Tang
- Telefoonnummer: +86 512 69359692
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Individuals with a new acute or subacute episode of visual loss or visual dysfunction in one or both eyes, for whom optic neuritis is included in the initial differential diagnosis at participating clinical centers. Each participant contributes only one clinical episode to the primary diagnostic accuracy cohort.
Beschrijving
Inclusion Criteria:
- Individuals presenting with a new acute or subacute episode of visual loss or visual dysfunction in one or both eyes, for whom optic neuritis is considered a reasonable differential diagnosis by the treating clinical team at the initial clinical assessment and before final diagnostic adjudication.
- Symptom onset of the current episode within 90 days before enrollment.
Exclusion Criteria:
1. The participant has previously been enrolled in this study. Each participant may be enrolled only once.
A history of optic neuritis or recurrent optic neuropathy before the current episode is not an exclusion criterion.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Aantal groepen / cohorten
Cohorten en interventies
Groep / CohortGroep / Cohort |
|---|
|
Suspected Optic Neuritis Differential-Diagnosis Cohort
Individuals with acute or subacute visual loss or visual dysfunction in whom optic neuritis is included in the differential diagnosis at initial clinical assessment. Participants undergo routine clinical evaluation, with study data collected using a structured case report form. The 2022 International Criteria for Optic Neuritis are evaluated alone and with the antibody-stratified adjunct. No treatment is assigned by the study. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diagnostic Performance of the 2022 International Criteria for Optic Neuritis
Tijdsspanne: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, with 95 percent confidence intervals, of the 2022 International Criteria for Optic Neuritis against Stage 2 full-information expert adjudication. Definite optic neuritis is index-positive and not optic neuritis is index-negative. Possible optic neuritis and indeterminate reference diagnoses are excluded from this conditional binary analysis and reported separately. |
Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diagnostic Yield of Definite Optic Neuritis Classification
Tijdsspanne: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
Among participants with optic neuritis according to Stage 2 full-information expert adjudication, the proportion classified as definite optic neuritis by the 2022 International Criteria for Optic Neuritis. Possible optic neuritis and not optic neuritis classifications remain in the denominator. |
Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
|
Diagnostic Performance of the Antibody-Stratified Adjunct in Participants With Aquaporin-4 Immunoglobulin G Positivity or Clear-Positive Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Results
Tijdsspanne: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
Among participants with aquaporin-4 immunoglobulin G positivity or clear-positive myelin oligodendrocyte glycoprotein immunoglobulin G results in the 3-month index window, diagnostic performance of the 2022 criteria alone and with the adjunct will be compared against Stage 2 full-information expert adjudication. Sensitivity, specificity, predictive values, and likelihood ratios with 95 percent confidence intervals will use the conditional and low-threshold definitions specified for the full-cohort comparison. Results will be reported for this subgroup overall and separately by antibody type. Definite-classification yield and reference diagnoses of newly upgraded cases will also be reported. Indeterminate reference diagnoses are excluded from binary accuracy calculations and reported separately. |
Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
|
Diagnostic Performance of the Low-Threshold 2022 Criteria Definition
Tijdsspanne: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios, with 95 percent confidence intervals, when definite or possible optic neuritis is index-positive and not optic neuritis is index-negative under the 2022 criteria. Stage 2 full-information expert adjudication is the reference standard. Indeterminate reference diagnoses are excluded from binary accuracy calculations and reported separately. |
Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
|
Diagnostic Performance of the 2022 International Criteria for Optic Neuritis With the Antibody-Stratified Adjunct
Tijdsspanne: Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
In the full cohort, performance of the 2022 criteria with the adjunct will be compared with the original criteria against Stage 2 full-information expert adjudication. In the conditional analysis, definite optic neuritis is positive and not optic neuritis is negative; possible optic neuritis is excluded. In the low-threshold analysis, definite or possible optic neuritis is positive and not optic neuritis is negative. Sensitivity, specificity, predictive values, likelihood ratios, and 95 percent confidence intervals will be reported. Definite-classification yield will also be compared in the same reference-positive participants, retaining possible classifications as not definite. Reference diagnoses of newly upgraded cases will be reported. Indeterminate reference diagnoses are excluded from binary accuracy calculations but reported separately. |
Index-test data within 3 months after symptom onset; reference-standard diagnosis up to 6 months after enrollment
|
|
Proportion of Indeterminate Reference-Standard Diagnoses
Tijdsspanne: Up to 6 Months After Enrollment
|
Proportion of participants assessed by the Stage 2 full-information expert adjudication panel whose reference-standard diagnosis is indeterminate. |
Up to 6 Months After Enrollment
|
|
Distribution of 2022 International Criteria for Optic Neuritis Classifications
Tijdsspanne: Baseline and diagnostic-window data for the current episode, within 3 months after symptom onset
|
Proportion of participants classified as definite optic neuritis, possible optic neuritis, or not optic neuritis by the 2022 International Criteria for Optic Neuritis. |
Baseline and diagnostic-window data for the current episode, within 3 months after symptom onset
|
|
Change in Expert-Adjudicated Diagnosis After Disclosure of Aquaporin-4 Immunoglobulin G and Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Results
Tijdsspanne: Paired adjudications using baseline and follow-up information available up to 6 months after enrollment
|
Among participants with at least one aquaporin-4 immunoglobulin G or myelin oligodendrocyte glycoprotein immunoglobulin G result available within the reference-standard information window and completed adjudications at both stages, the proportion whose diagnosis changes after disclosure. The direction of change between optic neuritis, non-optic neuritis, and indeterminate diagnoses will be reported, overall and by antibody status. Participants with neither antibody result available, or with an adjudication missing at either stage, are excluded from this proportion and reported separately. Diagnostic change is not assumed to represent correction of an error. |
Paired adjudications using baseline and follow-up information available up to 6 months after enrollment
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Yi Du, MD, PhD, First Affiliated Hospital of Guangxi Medical University
Publicaties en nuttige links
Algemene publicaties
- Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Galvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martinez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagreze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Munoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales AJ, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, van Pesch V, Wang AG, Wattjes MP, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022 Dec;21(12):1120-1134. doi: 10.1016/S1474-4422(22)00200-9. Epub 2022 Sep 27.
- Liang Y, Yang J, Luo W, Wei S, Wang K, Song R, Fu R, Zhao Y, Bai Y, Du Y. Diagnostic yield of the 2022 optic neuritis criteria and an antibody-stratified adjunct in an antibody-predominant Chinese clinical sample. Mult Scler Relat Disord. 2026 Jul;111:107212. doi: 10.1016/j.msard.2026.107212. Epub 2026 Apr 25.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- GX-ICON
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified participant-level data and a data dictionary will be made available to qualified researchers upon reasonable request after publication of the main diagnostic accuracy results, subject to ethics approval, institutional approval, and execution of a data use agreement.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .